Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX-61639 in SMARCA4-Mutated Advanced Solid Tumors
NCT07284186Phase 1Recruiting
- Sponsor
- Plexium
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLX-61639 in solid tumor, sponsored by Plexium. Primary endpoints: Treatment Emergent Adverse Events and Dose-Limiting Toxicities. Started Dec 2025; status: recruiting.
02
Drugs
PLX-61639
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07284186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284186.